修改的Gwakjeongtang对于腹占主导地位的刺激性肠综合征:随机,双盲,安慰剂控制,试点临床试验的研究协议
Yujin Choi1, Na-Yeon Ha2, Ae-Ran Kim3
1KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
International journal of general medicine
|April 29, 2024
概括
这项试点研究评估了对腹占主导地位的刺激性肠综合征 (IBS-D) 的修饰Gwakjeongtang (MGT). 该试验比较了MGT.
科学领域:
- 胃肠病学和肝病学
- 综合医学是一个整体的医学.
- 药理学 药理学 是一个学科.
背景情况:
- 刺激性肠综合征 (IBS) 是一种慢性胃肠疾病,影响全球数百万人.
- 修改的Gwakjeongtang (MGT) 是东亚传统的草药,具有潜在的抗炎和肠道保护性质.
- 对于IBS的MGT现有研究缺乏可靠的安慰剂对照数据.
研究的目的:
- 探索修改后的Gwakjeongtang (MGT) 在治疗腹占主导地位的刺激性肠综合征 (IBS-D) 的疗效和安全性.
- 在随机临床试验环境中,将MGT的效果与安慰剂进行比较.
- 为未来对IBS-D的MGT进行大规模临床研究奠定基础.
主要方法:
- 一项试点随机临床试验,涉及60名被诊断患有IBS-D的患者.
- 参与者将被随机分配,接受MGT或安慰剂4周.
- 主要结局指标包括腹痛强度和便一致性的变化.
主要成果:
- 数据收集和分析正在进行中; 结果正在等待.
- 这项研究旨在确定治疗后的整体反应率.
- 在IBS-D患者中将评估MGT的安全性和耐受性.
结论:
- 这些发现将提供关于MGT对IBS-D的有效性的初步证据.
- 这项研究将为更大规模的,最终的临床试验的设计提供信息.
- 结果将有助于理解MGT在综合性胃肠病学中的作用.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161
Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
157
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
157
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
118
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
118
Irritable Bowel Syndrome III: Medical and Nursing Management
197
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
197


